Cell Therapy Catapult Ltd:製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Cell Therapy Catapult Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C11239)・商品コード:DATA904C11239
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:44
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Cell Therapy Catapult Ltd (Catapult) is a provider of cell and gene therapy life cycle solutions. The company offers services such as industrialization, manufacturing, regulatory, health economics and market access, non-clinical safety and clinical operations. Its health economics and market access provide pricing and reimbursement and commercial management for gene therapies and other types of therapies. Catapult provides technology platform and clinical trials. The company also offers reimbursement and adoption of therapies. It partners healthcare sector and clinical researchers. Catapult is headquartered in London, the UK.

Cell Therapy Catapult Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cell Therapy Catapult Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cell Therapy Catapult Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cell Therapy Catapult Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cell Therapy Catapult Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cell Therapy Catapult Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Cell Therapy Catapult Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Cell Therapy Catapult Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Asymptote Enters into Licensing Agreement with Cell and Gene Therapy Catapult 13
Cell Therapy Catapult to Enter into Agreement with Japanese Society for Regenerative Medicine 14
Cell Therapy Catapult Enters into Agreement with Freeline Therapeutics 15
Cell Therapy Catapult and CombiGene Sign Agreement for CG01 16
Oxford BioMedica Enters into Agreement with Cell Therapy Catapult, Stratophase and Synthace 17
Cell Therapy Catapult Enters into Agreement with CRC for Cell Therapy Manufacturing 18
Cell Therapy Catapult Enters into partnership with Cooperative Research Centre for Cell Therapy Manufacturing 19
Cell Therapy Catapult Forms Joint Venture with University of Aberdeen 20
Synpromics Enters into Agreement with Cell Therapy Catapult 21
Cell Therapy Catapult Enters into Joint venture Agreement with University of Birmingham and Cancer Research Technology 22
Asterias Biotherapeutics Enters into Agreement with Cell Therapy Catapult 23
Cell Therapy Catapult Enters into Agreement with Asymptote 24
Cell Therapy Catapult, Plasticell and University of Oxford Enter into Agreement 25
TAP Biosystems Enters into Agreement with Cell Therapy Catapult 26
Cell Therapy Catapult, Azellon, University of Liverpool and NHS Blood and Transplant Enter into Agreement 27
Cell Therapy Catapult Enters into Agreement with Athersys 28
Cell Therapy Catapult Enters into Research Agreement with TrakCel 29
Cell Therapy Catapult Forms Catapult Therapy TCR with UCL Business and Imperial Innovations 30
ReNeuron Enters Into Co-Development Agreement With Cell Therapy Catapult 31
Licensing Agreements 32
Cell Therapy Catapult Enters into Licensing Agreement with iPS Academia Japan 32
Acquisition 33
Cell Medica Acquires Catapult Therapy TCR from Cell Therapy Catapult 33
Cell Therapy Catapult Ltd – Key Competitors 34
Cell Therapy Catapult Ltd – Key Employees 35
Cell Therapy Catapult Ltd – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Joint Venture 36
Recent Developments 37
Corporate Communications 37
Oct 18, 2018: CGT Catapult names Three New Board Members 37
Jun 06, 2018: Cell and Gene Therapy Catapult Appoints Dr Jonathan Appleby As Chief Scientific Officer 39
Other Significant Developments 40
May 16, 2018: CGT Catapult announces major UK investment in skills and capabilities 40
Feb 28, 2018: CGT Catapult holds inaugural Seminar Series 41
Jan 08, 2018: Adaptimmune Announces Two Manufacturing Achievements on Its way to Become the First Fully Integrated TCR T-cell Therapy Company 42
Nov 13, 2017: Cell and Gene Therapy Catapult research highlights the UK’s growing global leadership in innovative cell and gene therapy industry 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Cell Therapy Catapult Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Cell Therapy Catapult Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cell Therapy Catapult Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cell Therapy Catapult Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cell Therapy Catapult Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Cell Therapy Catapult Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Cell Therapy Catapult Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Asymptote Enters into Licensing Agreement with Cell and Gene Therapy Catapult 13
Cell Therapy Catapult to Enter into Agreement with Japanese Society for Regenerative Medicine 14
Cell Therapy Catapult Enters into Agreement with Freeline Therapeutics 15
Cell Therapy Catapult and CombiGene Sign Agreement for CG01 16
Oxford BioMedica Enters into Agreement with Cell Therapy Catapult, Stratophase and Synthace 17
Cell Therapy Catapult Enters into Agreement with CRC for Cell Therapy Manufacturing 18
Cell Therapy Catapult Enters into partnership with Cooperative Research Centre for Cell Therapy Manufacturing 19
Cell Therapy Catapult Forms Joint Venture with University of Aberdeen 20
Synpromics Enters into Agreement with Cell Therapy Catapult 21
Cell Therapy Catapult Enters into Joint venture Agreement with University of Birmingham and Cancer Research Technology 22
Asterias Biotherapeutics Enters into Agreement with Cell Therapy Catapult 23
Cell Therapy Catapult Enters into Agreement with Asymptote 24
Cell Therapy Catapult, Plasticell and University of Oxford Enter into Agreement 25
TAP Biosystems Enters into Agreement with Cell Therapy Catapult 26
Cell Therapy Catapult, Azellon, University of Liverpool and NHS Blood and Transplant Enter into Agreement 27
Cell Therapy Catapult Enters into Agreement with Athersys 28
Cell Therapy Catapult Enters into Research Agreement with TrakCel 29
Cell Therapy Catapult Forms Catapult Therapy TCR with UCL Business and Imperial Innovations 30
ReNeuron Enters Into Co-Development Agreement With Cell Therapy Catapult 31
Cell Therapy Catapult Enters into Licensing Agreement with iPS Academia Japan 32
Cell Medica Acquires Catapult Therapy TCR from Cell Therapy Catapult 33
Cell Therapy Catapult Ltd, Key Competitors 34
Cell Therapy Catapult Ltd, Key Employees 35
Cell Therapy Catapult Ltd, Subsidiaries 36
Cell Therapy Catapult Ltd, Joint Venture 36

List of Figures
Cell Therapy Catapult Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cell Therapy Catapult Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cell Therapy Catapult Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cell Therapy Catapult Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cell Therapy Catapult Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cell Therapy Catapult Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Cell Therapy Catapult Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cell Therapy Catapult Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cell Therapy Catapult Ltd, Medical Devices Deals, 2012 to YTD 2018 10

★調査レポート[Cell Therapy Catapult Ltd:製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C11239)販売に関する免責事項を必ずご確認ください。
★調査レポート[Cell Therapy Catapult Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆